Show simple item record

dc.contributor.authorBalieva, Flora Nicol
dc.contributor.authorCatton, Louise
dc.contributor.authorClaréus, Birgitta W.
dc.contributor.authorDanielsen, Kjersti
dc.contributor.authorFierens, Frederik
dc.contributor.authorIversen, Lars
dc.contributor.authorKoulu, Leena
dc.contributor.authorOsmanecevic, Amra
dc.contributor.authorPasternack, Rafael
dc.contributor.authorSkov, Lone
dc.date.accessioned2023-11-13T13:55:56Z
dc.date.available2023-11-13T13:55:56Z
dc.date.created2023-09-15T16:19:42Z
dc.date.issued2023
dc.identifier.citationBalieva, F.N., Catton, L., Claréus, B.W., Danielsen, K., Fierens, F., Iversen, L., Koulu, L., Osmanecevic, A., Pasternack, R. & Skov, L. (2023) Treatment Preferences in Young Adults with Moderate to Severe Psoriasis: A Qualitative Study from the Nordic Countries. Dermatology and Therapy, 13, 1873–1887en_US
dc.identifier.issn2193-8210
dc.identifier.urihttps://hdl.handle.net/11250/3102228
dc.description.abstractIntroduction The purpose of this study is to explore treatment preferences and identify patient characteristics in young bio-naive adults with moderate to severe psoriasis in the Nordic countries (Norway, Finland, Sweden, and Denmark). Methods Patients were 18–45 years old and bio-naive but referred for biologic treatment of moderate to severe psoriasis. Patients were included at eight Nordic dermatology clinics. Patients with significant comorbidity or psoriatic arthritis were excluded. The Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI) were assessed along with basic patient information. A semistructured interview guide was used in individual qualitative interviews, asking patients about their treatment preferences and reasons, disease journey, and disease management. The interviews were analyzed using thematic content analysis. Twenty-four patients sufficed to reach saturation in this qualitative study. Results The patient sample characteristics represented a qualitative variation in age, sex, symptoms, duration of disease, and country. We included a total of 12 male and 12 female patients. The mean age was 34 years (range 18–45 years), the mean age at diagnosis was 20 years (range 6–34 years), the mean ± standard deviation (SD) time since diagnosis was 13 ± 8 years, PASI was 9.5 ± 4.7, and DLQI was 15.2 ± 6.4. Interviews suggested that both the burden of disease as well as the burden of treatment influenced patient preferences regarding treatment attributes, hence getting alleviation from symptoms did not alone influence patient preferences. Time, effort, and inconvenience related to psoriasis treatments also influenced patient preferences. Conclusions This first in-depth, qualitative study in young bio-naive adults with psoriasis suggests that patient preferences are focusing not only on symptom relief but also on alleviating the burden of psoriasis treatment. Understanding the reasons for patient preferences and the perspectives of young adults is needed to guide individual shared decision-making in psoriasis management.en_US
dc.language.isoengen_US
dc.publisherSpringer Nature Switzerland AGen_US
dc.rightsNavngivelse 4.0 Internasjonal*
dc.rightsNavngivelse-Ikkekommersiell 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/deed.no*
dc.subjectpsoriasisen_US
dc.titleTreatment Preferences in Young Adults with Moderate to Severe Psoriasis: A Qualitative Study from the Nordic Countriesen_US
dc.typePeer revieweden_US
dc.typeJournal articleen_US
dc.description.versionpublishedVersionen_US
dc.rights.holder© 2023 The Author(s).en_US
dc.subject.nsiVDP::Medisinske Fag: 700::Klinisk medisinske fag: 750en_US
dc.source.pagenumber1873-1887en_US
dc.source.volume13en_US
dc.source.journalDermatology and Therapyen_US
dc.source.issue8en_US
dc.identifier.doi10.1007/s13555-023-00973-5
dc.identifier.cristin2175587
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Navngivelse 4.0 Internasjonal
Except where otherwise noted, this item's license is described as Navngivelse 4.0 Internasjonal